Mixed ovarian germ cell tumor in a BRCA2 mutation carrier

International Journal of Gynecological Pathology

Volumn 26, Issue 2, 2007, Pages 160-164

  Hamel, Nancy ^a,b   Wong, Nora ^a,c   Alpert, Lesley ^c   Galvez, Maria ^b   Foulkes, William D ^a,b,c  

^a Departments of Human Genetics and Medicine   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

BRCA2; Germ cell tumor; LOH; Ovarian cancer

Indexed keywords

BLEOMYCIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; VINBLASTINE;

ADULT; ALLELE; ARTICLE; BREAST CANCER; CASE REPORT; CHORIOCARCINOMA; DNA DETERMINATION; DYSGERMINOMA; EMBRYONAL CARCINOMA; EPITHELIUM TUMOR; FEMALE; GENE MUTATION; GERM CELL TUMOR; HETEROZYGOSITY LOSS; HETEROZYGOTE; HUMAN; HUMAN TISSUE; MIXED TUMOR; MULTIPLE CYCLE TREATMENT; OVARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; TERATOMA;

ADULT; BRCA2 PROTEIN; CARCINOMA, EMBRYONAL; CHORIOCARCINOMA; DYSGERMINOMA; FEMALE; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; JEWS; LOSS OF HETEROZYGOSITY; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; OVARIAN NEOPLASMS; PEDIGREE; TERATOMA;

EID: 34147136187     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pgp.0000228142.52054.0f     Document Type: Article

References (12)

1. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999;91:1310Y6.
2. Parkin D, Whelan S, Fearly J, et al, eds. Cancer Incidence in 5 Continents. IARC Scientific Publications No. 143. Lyon: IARC; 1997.
3. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol 2005;18:S19Y32.
4. Moslehi R, Chu W, Karlan B, et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 2000;66:1259Y72.
5. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000;283:2260Y5.
6. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117Y30.
7. Hilton JL, Geisler JP, Rathe JA, et al. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 2002;94:1396Y406.
8. Gras E, Cortes J, Diez O, et al. Loss of heterozygosity on chromosome 13q12Yq14, BRCA-2 mutations and lack of BRCA-2 promoter hypermethylation in sporadic epithelial ovarian tumors. Cancer 2001;92:787Y95.
9. Foster KA, Harrington P, Kerr J, et al. Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer. Cancer Res 1996;56:3622Y5.
10. Werness BA, Ramus SJ, Whittemore AS, et al. Primary ovarian dysgerminoma in a patient with a germline BRCA1 mutation. Int J Gynecol Pathol 2000;19:390Y4.
11. Santarosa M, Ashworth A. Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way. Biochim Biophys Acta 2004;1654:105Y22.
12. Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Ins 2000;92:564Y9.